TrialOrphanet journal of rare diseases2017

Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects.

N Guérard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.